The aim of this study was to describe the pediatric population with ADHD and their pharmacological treatment. Using the Swedish National Patient Register and the Prescribed Drug Register we identified individuals below 19 years of age who were diagnosed or medically treated for ADHD for the first time 2006-2007. The unique patient identifiers were used to link information from the two registers to describe demographic characteristics, hospital care and drug treatments. Logistic regression model estimated the association between age, sex, frequency of hospitalization, diagnosis or treatment for other mental disorders and risk of gap in the treatment. Totally the study included 7,931 patients of whom 74% were males. The mean age at first diagnosis was 12 years. Some 84% were medically treated for ADHD and approximately 90% received methylphenidate as the first substance. Combination therapy was rare and the most common combination was methylphenidate and atomoxetine. More than 55% of the patients, which could be followed up for two years after start of treatment, had at least one treatment gap of six months. Older age at diagnosis, lower number of hospitalizations and comorbidity with other mental disorders increased risks of gaps in medication. Approximately one fifth of the patients recorded in the National Patient Register as diagnosed with ADHD did not receive pharmacological treatment. Medication adherence seems to be low, when measured as gaps in treatment.
Introduction
Attention Deficit Hyperactivity Disorder (ADHD), characterized by concentration difficulties, hyperactivity and impulsivity, affects 5 to 10 percent of children and adolescents and approximately 4% of adults. (Biederman, 2005) In Sweden 3-6% of children in school age are diagnosed with this disorder and it seems that males have 2-3 fold higher risks. (Socialstyrelsen, 2004) Patients with a diagnosis of ADHD have increased risks for other psychiatric morbidity and social problems. The children with ADHD are at higher risk of becoming drug abusers later in life. (Yoshimasu et al., 2012) Approximately 80% of children and adults with ADHD reported to have at least one additional mental disorder, such as oppositional defiant disorder, anxiety disorder and depression. (Kadesjo and Gillberg, 2001; Rodriguez et al., 2007) Pharmacological treatment of ADHD should be considered when psychological treatments are insufficient alone or if the criteria for Hyperkinetic Disorder according to ICD-10 criteria are fulfilled. (Taylor et al., 2004) According to the European recommendation methylphenidate should be the first choice. (Taylor et al., 2004) A recent study (Zoega et al., 2011) showed that a considerable national variation in use of ADHD drugs exists between the Nordic countries. However, the study found that methylphenidate was the most commonly used ADHD drug in all countries. Zetterqvist et al. (Zetterqvist et al., 2012 ) in a populationbased Swedish study reported an increase in the number of prescriptions dispensed for ADHD drugs from 2006 to 2009 and a high rate of treatment discontinuation among these patients.
Recently, Janols et al. (Janols et al., 2009 ) described the use of central stimulants in ADHD in Sweden using information from the Medical Products Agency's database on named patient use. Information on demographic characteristics, such as age, sex, and concomitant drug treatment was, however, not addressed.
Aims of the study
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The aims of this study were to describe pharmacological treatment and factors influencing medically treatment in pediatric patients diagnosed with ADHD. In particular, we investigated A) association between some important characteristic factors -including age, frequency of hospital contact, diagnosis of other psychiatric disorders, and use of other classes of psychotropic medications -on the one hand and initiation of pharmacological treatment for ADHD and gap in treatment on the other B) type of medication received by the patients, combination therapy and lack time between diagnosis and pharmacological treatment C) proportion of patients in the cohort who are treated with psychotropic drugs other than ADHD drug.
Experimental Procedures
All patients who, for the first time, received a diagnosis of ADHD or treatment for 
Statistical analyses
We estimated the incidence of ADHD during the study period and prevalence of pharmacological treatment in the Swedish population below 19 years of age (n=2,055,847).
Pharmacological treatment was assessed by substance. We also performed stratified analyses by sex, age (age groups: <5, 5-9, 10-14, 15-18), ward level (in-patient versus out-patient) and residential place (the six Swedish health-care regions i.e. Uppsala-Örebro, StockholmGotland, South, South-east, West and North).
The prevalence of combination therapies, and gaps in pharmacological treatment were also investigated. Combination therapy was defined as having a dispensing of two or more ADHD drugs during a period of six-month. Gap in treatment was defined as no purchase during a period of six-month followed by a resume of medication. The gaps were counted during a period of two years among children and adolescents who had at least two years follow-up after the start of pharmacological treatment (n=5,985). The cumulative incidence of pharmacological treatment -the probability of receiving pharmacological treatment -after a diagnosis of ADHD was also estimated. Moreover, we investigated if the patients in the cohort had any record of other psychiatric disorders or treatment with other classes of psychotropic medications from July 2005 to the end of the study period.
Logistic regression models were used to investigate the association between demographic factors and risk of initiating ADHD treatment. As demographic factors we included sex, age (age groups: <5, 5-9, 10-14, 15-18), frequency of hospital contact (number of records: 1, 2-3, >3), history of other psychiatric disorders (yes, no; ICD-10 codes: F00-F99 or the corresponding codes according to the earlier versions of ICD, and excluding the codes for ADHD) and treatment with other classes of psychotropic medications (yes, no). For those who received pharmacological treatment we studied the association between these factors and risk of having a gap in medication. We used univariate models to estimate the crude relative risks and multivariate analyses to estimate adjusted relative risks.
As the diagnostic accuracy of ADHD could be a concern we reanalyzed the data restricted to those who had at least two recorded episodes with a diagnosis of ADHD in the Patient Register. Moreover, we studied characteristics of the individuals who filled prescriptions for drugs used for treatment of ADHD but with no record in the National Patient
Register.
The study was approved by the regional ethics board at Karolinska Institutet.
Results
The of the cohort received at least one of the substances used for treatment of ADHD. Multivariate analysis showed no significant association between sex and treatment for ADHD. Adolescents 10-14 years old at entry had the highest risks for pharmacological treatment and number of hospital contacts was positively associated with probability of treatment (table 2) . Patients treated with other classes of psychotropic medications had higher risks for pharmacological treatment for ADHD compared with those who were not treated with these medications.
Of the 5,380 patients with ADHD in the National Patient Register 81% had two or more records with the diagnosis and 76% had received at least one of the substances used for treatment of ADHD. Characteristics of the 2,551 individuals who filled prescriptions for an ADHD drug, but with no record in the National Patient register were similar to those with records in both registers (data not shown).
Pharmacological treatment
Methylphenidate and atomoxetine were first line of therapy for treating the majority of patients and amphetamine and dexamfetamine were rarely used (Table 3) .
Among the 6,649 patients with ADHD and drug treatment 2,708 (40.7%) received only long-acting methylphenidate during the study period, 1,213 (18.2%) had both long-and shortacting methylphenidate and 382 (5.7%) had not received methylphenidate during the study period. The remaining 2,346 (35.3%) patients were treated with methylphenidate and one of the other substances.
The number of patients who purchased ADHD drugs for the first time varied by season.
The lowest dispensing was in July and December. During the study period an increasing number of patients initiated treatment with drugs used for ADHD. Approximately 65% of those diagnosed with ADHD received at least one medication up to one year after the diagnosis and at the end of follow-up nearly 82% had ever had pharmacological treatment (Figure 1 ).
The number of defined daily dose for each prescription was estimated based on the package size and recorded in the Swedish Prescribed Drug Register. Based on the estimated defined daily doses the mean duration of the prescriptions for different substances were between 22 and 76 days.
The ADHD drugs were mainly prescribed by pediatricians (42%), pediatric psychiatrists (38%), and psychiatrists (11%).
Geographical differences
Rates of ADHD diagnosis differed between the different regions of Sweden (less than 165 new cases per 100,000 inhabitants per year in the southern regions versus 225 cases in the Western regions) and so did drug treatments. The Western regions had the highest rate of dispensed prescriptions with methylphenidate (4,554/100 000 inhabitants compared with 2,664/100 000 inhabitants in southeast). Atomoxetine was used most frequently in the Central region (1,235/100 000 inhabitants compared with 699/100 000 inhabitants in southeast).
Combination therapy, gap in treatment and medication adherence
Of the 6,649 patients with ADHD and drug treatment, 302 (4.5 %) had received at least two drugs, and atomoxetine was the most common drug in combination therapy. A total of 4,946 (74.4%) patients received only one substance, 1,670 (25.1%) two substances and 33 (0.5 %) received three substances or more.
Single use was rare, with 456 (6.9%) having one dispensing only (6.3% methylphenidate, and 0.6% atomoxetine) and 358 (6.3 %) with two dispensings. When we restricted the analyses to include only the 5,985 patients who had at least two years of followup after start of pharmacological treatment, 2,609 (43.6%) patients had one six-month-gap in their treatment, and 241 (4.0%) patients had two or more gaps. There was a higher proportion of females with one or more gaps in treatment when compared to males (53% versus 46%).
However, multivariate analysis showed no significant differences between males and females (table 2) . Age below five years or several hospital contacts were associated with decreased risks of having a gap in pharmacological treatment. Those with a record of other mental disorders had 30% increased risk of having gap (OR=1.3, 95% CI 1.2-1.5). Approximately 40% of the patients stopped their medication during the last six months of follow-up which could be a gap or discontinuation.
Other psychiatric disorders
Approximately half of the patients had at least one record with other mental disorders in the National Patient Register, such as a depressive episode, panic disorder, generalized anxiety disorder or pervasive developmental disorders. Females had more often other psychiatric disorders compared with males (57% versus 45%, p < 0.01).
A third of the patients had at least one other psychotropic medication, such as hypnotics, sedatives or antidepressants (table 4) . Females had more often hypnotics and sedatives compared with males (43% versus 29%, p < 0.01)
There was practically no impact on the results when the analyses were restricted to those who had at least two records of an ADHD diagnosis (data not shown in tables).
Discussion
This nationwide study showed that a majority of the patients in hospital in-or outpatient care received medications for their disorder up to one year after being diagnosed with ADHD.
Two years after the initial diagnosis 20 percent had no medication for ADHD.
Methylphenidate was the most common drug, particularly long-acting methylphenidate.
Adolescents 10-14 years old at entry had the highest risks for pharmacological treatment and number of hospital contacts was positively associated with probability of treatment. We observed also that patients treated with other classes of psychotropic medications had higher risks for pharmacological treatment for ADHD compared with those who were not treated with these medications. Combination therapy was rare and the most common combination therapy was methylphenidate and atomoxetine. More than half of the patients had one or more treatment gaps of six-months during a two-year period.
Amphetamine and dexamphetamine are rarely used for treating ADHD patients in The data showed considerable differences in rate of ADHD and drug treatment in different regions of Sweden, but also within different quite similar countries with similar healthcare resources (Zoega, et al., 2011) . The regional differences are consistent with what has been recorded from other countries. (Cohen and Hesselbart, 1993; Gumy et al., 2010) Variation in adaption of new information and awareness of the problems related to ADHD among parents, teachers, and physicians could be the reason for the observed geographical differences in the diagnosis and treatment. (Bussing et al., 2003) The level of availability and distribution of healthcare resources such as specialist clinics and specialists cannot explain the regional differences of diagnosis or prescription. (Socialstyrelsen, 2010b) The low medication adherence among patients with ADHD is also consistent with the findings in previous studies. (Hodgkins et al., 2011; Marcus and Durkin, 2011; McCarthy et al., 2009; Zetterqvist et al., 2012) This study showed that more than half of the patients had one or more treatment gaps of six-months during a two-year period. The reasons for the poor adherence are unknown to us and the data, which can be obtained from the registers does not allow for analysis of how disease severity and psychological development may affect medication adherence. Low risk of gaps among the youngest age group could be explained by a higher support by parents or their possibility to influence their child's medication. It is possible that those with gaps in treatment had less severe ADHD. However, the results in which those with higher number of hospital contact had lower adherence is not consistent with this speculation as the most severe cases are more impulsive and inattentive. Clinical experience also shows that in many cases entrance into adolescence results in refusal to take psychotropic medication. Moreover, those with diagnosis or treatment for other classes of psychotropic medications had poorer adherence. It is also possible that the observed gaps were the periodic medication free periods recommended by their physicians. However, a medication free period should last not more than a few weeks. (van de Loo-Neus et al., 2011) Therefore, a gap of six-months should be considered as low medication adherence. It has been reported that the beneficial effect of stimulant medications appears to stop working two to three years after treatment has been initiated. (Nieweg, 2010; van de Loo-Neus et al., 2011) The high proportion of the patients who stopped their medication after two years in this study is consistent with previous reports. It is worth mentioning that data on the effectiveness of long-term atomoxetine treatment is lacking (van de Loo-Neus et al., 2011) and due to small number of patients who were prescribed only atomoxetine we could not investigate its longterm effectiveness.
The strengths of our study include the large sample size and population based design, but the study also has some limitations. Considering that ADHD is primarily treated in outpatient setting some patients might not be included in our cohort. Therefore, the estimated incidence might be an underestimation of the real incidence. Another caveat is that we did not have information on the indications for treatment, but it should be noted that ADHD is the only licensed indication for methylphenidate and atomoxetine use in Sweden. To our best of knowledge there is no established definition for a gap in treatment for patients with ADHD and the defined gap in this study was determined based on treatment routines for ADHD and the characteristics of the data. Treatment practices for patients with ADHD include shorter gaps such as stopping medication during weekends and summer holidays. Moreover, according to the rules in Sweden a dispensing lasts a maximum of three months. Therefore, we applied a conservative approach and defined a gap in treatment as no purchase during a period of six-month.
In conclusion, the number of patients diagnosed and treated for ADHD is increasing, which could be due to an increased awareness about this disorder. Approximately one fifth of patients recorded with an ADHD diagnosis were not medically treated and among those treated gaps in treatment were common. Methylphenidate was the first line therapy choice and combination therapy was rare. 
